Marinus Pharma

Marinus Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Company Details

Employees
50
Address
5 Radnor Corporate Center, 100 Matsonford Rd,
Phone
484-253-6792
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Radnor, PA
Looking for a particular Marinus Pharma employee's phone or email?

Marinus Pharma Questions

News

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. Business Wire

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder - ir.marinuspharma.com

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder ir.marinuspharma.com

Inside INdiana Business - FinancialContent

Inside INdiana Business FinancialContent

Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label, dose‐finding, phase 2 trial - Vaitkevicius - 2022 - Epilepsia - Wiley Online Library

Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label, dose‐finding, phase 2 trial - Vaitkevicius - 2022 - Epilepsia Wiley Online Library

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day - Stock Titan

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day Stock Titan

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Business Wire

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder - Stock Titan

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder Stock Titan

About Us - FinancialContent

About Us FinancialContent

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder - Business Wire

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder Business Wire

User - FinancialContent

User FinancialContent

Top Marinus Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant